Invasive aspergillosis in critically ill patients without malignancy.

Using criteria designed for invasive aspergillosis (IA) in patients with cancer, we aimed to determine the impact of IA in patients without malignancy in a medical intensive care unit (ICU). In this retrospective study, 127 patients out of 1,850 admissions (6.9%) hospitalized between 2000 and 2003 had microbiological or histopathologic evidence of Aspergillus during their ICU stay. There were 89 cases (70%) without hematologic malignancy. These patients were classified as proven IA (n = 30), probable IA (n = 37), possible IA (n = 2), or colonization (n = 20). In these patients, mean SAPS II score was 52 with a predicted mortality of 48%. The observed mortality was 80% (n = 71). Mortality of the proven and the probable IA was 97 and 87%, respectively. Postmortem examination was done in 46 out of 71 patients, and 27 autopsies (59%) showed hyphael invasion with Aspergillus. Aspergillus infections occurred in five critically ill patients with proven IA who did not have any predisposing factors according to the currently available definitions. Three of these patients had Child C liver cirrhosis. IA is an emerging and devastating infectious disease in patients in the ICU without malignancy. In those patients, host criteria for probable fungal infections should probably be adapted.

[1]  A. Sulahian,et al.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. , 2003, The New England journal of medicine.

[2]  D. Kontoyiannis,et al.  Glucocorticoids and invasive fungal infections , 2003, The Lancet.

[3]  D. Denning.  Echinocandin antifungal drugs , 2003, The Lancet.

[4]  D. Denning,et al.  Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Vincent,et al.  Disseminated Aspergillosis in Intensive Care Unit Patients: An Autopsy Study , 2003, Journal of chemotherapy.

[6]  D. Annane,et al.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. , 2002, JAMA.

[7]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[8]  E. Anaissie,et al.  Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  W. Webb,et al.  The Radiologic Spectrum of Pulmonary Aspergillus Infections , 2002, Journal of computer assisted tomography.

[10]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Verhaegen,et al.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.

[12]  M. Delos,et al.  Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? , 2001, Intensive Care Medicine.

[13]  A. Wilmer,et al.  Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings. , 2000, Mayo Clinic proceedings.

[14]  Burton Ec,et al.  Medical error and outcomes measures: where have all the autopsies gone? , 2000 .

[15]  D. Denning,et al.  Practice Guidelines for Diseases Caused by Aspergillus , 2000 .

[16]  Nina Singh,et al.  Invasive aspergillosis in transplant recipients. , 1999, Medicine.

[17]  R Sylvester,et al.  An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. , 1998, The Journal of infection.

[18]  J. Rello,et al.  Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  N. Müller,et al.  Invasive aspergillosis in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage. , 1998, Clinical radiology.

[20]  H. Moecke,et al.  Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients , 1997, Intensive Care Medicine.

[21]  M. J. Schiff,et al.  Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. , 1991, Thorax.

[22]  V. Devita,et al.  Aspergillosis. The spectrum of the disease in 98 patients. , 1970, Medicine.

[23]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.